HIV gp160 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
出版信息
Drugs R D. 1999 Jun;1(6):451-2. doi: 10.2165/00126839-199901060-00006.
Abstract
摘要
相似文献
1
HIV gp160 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
Drugs R D. 1999 Jun;1(6):451-2. doi: 10.2165/00126839-199901060-00006.
2
HIV gp120 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
Drugs R D. 1999 Jun;1(6):448. doi: 10.2165/00126839-199901060-00004.
3
HIV gp160 vaccine (Immuno AG).
Drugs R D. 1999 Jun;1(6):449-50. doi: 10.2165/00126839-199901060-00005.
4
Immunisation with gp160 in HIV-1 infection.
Lancet. 1999 Sep 11;354(9182):948-9. doi: 10.1016/S0140-6736(05)75694-4.
5
Immunisation with gp160 in HIV-1 infection.
Lancet. 1999 Sep 11;354(9182):948; author reply 949. doi: 10.1016/S0140-6736(05)75693-2.
6
HIV vaccine vCP205. ALVAC-HIV vCP205, ALVAC vCP205.
Drugs R D. 1999 Jun;1(6):459-60. doi: 10.2165/00126839-199901060-00009.
7
HIV gp120 vaccine (Chiron).
Drugs R D. 1999 Jun;1(6):445-7. doi: 10.2165/00126839-199901060-00003.
8
Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
Expert Rev Vaccines. 2007 Jun;6(3):289-91. doi: 10.1586/14760584.6.3.289.
9
PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
Science. 2015 Jul 24;349(6246):386-7. doi: 10.1126/science.aac6300. Epub 2015 Jul 23.
10
The rationale behind a vaccine based on multiple HIV antigens.
Microbes Infect. 2005 Nov;7(14):1414-23. doi: 10.1016/j.micinf.2005.07.017. Epub 2005 Sep 29.
Zotero 插件